A novel method for assessing inhibition of ibuprofen chiral inversion and its application in drug discovery

International Journal of Pharmaceutics

Volumn 335, Issue 1-2, 2007, Pages 63-69

  Reddy, Anita ^a   Hashim, Muhammed ^a   Wang, Ziqiang ^a   Penn, Lara ^a   Stankovic, Charles J ^a   Burdette, Douglas ^a   Surendran, Narayanan ^a   Cai, Hongliang ^a  

^a PFIZER INC   (United States)

Author keywords

Chiral inversion; Enantiomer; Ibuprofen; Inhibition

Indexed keywords

FENOPROFEN; IBUPROFEN; IBUPROFEN DERIVATIVE; KETOPROFEN; THALIDOMIDE;

ANIMAL CELL; ARTICLE; CHIRALITY; CONTROLLED STUDY; CRYOPRESERVATION; DOG; DRUG INHIBITION; DRUG RESEARCH; ENANTIOMER; ENZYMATIC ASSAY; ENZYME ACTIVE SITE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; LIVER CELL; MASS SPECTROMETRY; MONKEY; NONHUMAN; PRIORITY JOURNAL; RAT; SEPARATION TECHNIQUE; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; VALIDATION STUDY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING, COMPETITIVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COENZYME A LIGASES; CRYOPRESERVATION; DOGS; DRUG DESIGN; HEPATOCYTES; HYDROLASES; IBUPROFEN; INJECTIONS, INTRAVENOUS; KINETICS; MACACA FASCICULARIS; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; RACEMASES AND EPIMERASES; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TANDEM MASS SPECTROMETRY;

EID: 33947722903     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.11.006     Document Type: Article

References (18)

1. Baillie T.A., Adams W.J., Kaiser D.G., Olanoff L.S., Halstead G.W., Harpootlian H., and Van Giessen G.J. Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans. J. Pharmacol. Exp. Ther. 249 (1989) 517-523
2. Bruggera R., Reichel C., Garcia Alia B., Brune K., Yamamoto T., Tegeder I., and Geisslinger G. Expression of rat liver long-chain acyl-CoA synthetase and characterization of its role in the metabolism of R-ibuprofen and other fatty acid-like xenobiotics. Biochem. Pharmacol. 61 (2001) 651-656
3. Drayer D.E. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview. Clin. Pharmacol. Ther. 40 (1986) 125-133
4. Hubbard J.W., Ganes D., Lim H.K., and Midha K.K. Chiral pharmacology and its consequences for therapeutic monitoring. Clin. Biochem. 19 (1986) 107-112
5. Hutt A.J., and O'Grady J. Drug chirality: a consideration of the significance of the stereochemistry of antimicrobial agents. J. Antimicrob. Chemother. 37 (1996) 7-32
6. Jamali F. Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs. Eur. J. Drug Metab. Pharmacokinet. 13 (1988) 1-9
7. Kaiser D.G., Vangiessen G.J., Reischer R.J., and Wechter W.J. Isomeric inversion of ibuprofen (R)-enantiomer in humans. J. Pharm. Sci. 65 (1976) 269-273
8. Knihinicki R.D., Day R.O., and Williams K.M. Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs-II. Racemization and hydrolysis of (R)- and (S)-ibuprofen-CoA thioesters. Biochem. Pharmacol. 42 (1991) 1905-1911
9. Landoni M.F., and Soraci A. Pharmacology of chiral compounds: 2-arylpropionic acid derivatives. Curr. Drug Metab. 2 (2001) 37-51
10. Menzel S., Sauernheimer C., Brune K., and Geisslinger G. Is the inversion from R- to S-ketoprofen concentration dependent? Investigations in rats in vivo and in vitro. Biochem. Pharmacol. 47 (1994) 1267-1270
11. Muller N., Payan E., Lapicque F., Bannwarth B., and Netter P. Pharmacological aspects of chiral nonsteroidal anti-inflammatory drugs. Fundam. Clin. Pharmacol. 4 (1990) 617-634
12. Reist M., Carrupt P.A., Francotte E., and Testa B. Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem. Res. Toxicol. 11 (1998) 1521-1528
13. Sanins S.M., Adams W.J., Kaiser D.G., Halstead G.W., and Baillie T.A. Studies on the metabolism and chiral inversion of ibuprofen in isolated rat hepatocytes. Drug Metab. Dispos. 18 (1990) 527-533
14. Sanins S.M., Adams W.J., Kaiser D.G., Halstead G.W., Hosley J., Barnes H., and Baillie T.A. Mechanistic studies on the metabolic chiral inversion of R-ibuprofen in the rat. Drug Metab. Dispos. 19 (1991) 405-410
15. Tanner M.E. Understanding nature's strategies for enzyme-catalyzed racemization and epimerization. Acc. Chem. Res. 35 (2002) 237-246
16. Wechter W.J. Drug chirality: on the mechanism of R-aryl propionic acid class NSAIDs. Epimerization in humans and the clinical implications for the use of racemates. J. Clin. Pharmacol. 34 (1994) 1036-1042
17. Wsol V., Skalova L., and Szotakova B. Chiral inversion of drugs: coincidence or principle?. Curr. Drug Metab. 5 (2004) 517-533
18. Xiaotao Q., and Hall S.D. Modulation of enantioselective metabolism and inversion of ibuprofen by xenobiotics in isolated rat hepatocytes. J. Pharmacol. Exp. Ther. 266 (1993) 845-851